Bio-Rad Laboratories, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | $2.15 | $2.15 | $2.15 |
| Q2 2024 | 1 | $2.01 | $2.01 | $2.01 |
| Q3 2024 | 1 | $1.14 | $1.18 | $1.16 |
| Q4 2024 | 4 | $2.75 | $2.96 | $2.86 |
| Q1 2025 | 4 | $2.49 | $2.81 | $2.66 |
| Q2 2025 | 2 | $2.97 | $3.07 | $3.01 |
| Q3 2025 | 2 | $2.86 | $2.97 | $2.91 |
| Q4 2025 | 2 | $3.02 | $3.13 | $3.07 |
| Q1 2026 | 1 | $2.77 | $2.87 | $2.81 |
| Q2 2026 | 1 | $3.02 | $3.13 | $3.07 |
| Q3 2026 | 1 | $3.23 | $3.35 | $3.28 |
| Q4 2026 | 1 | $3.52 | $3.65 | $3.58 |
Bio-Rad Laboratories, Inc. Earnings Date And Information
Bio-Rad Laboratories, Inc. last posted its earnings results on Wednesday, October 30th, 2024. The company reported $2.01 earnings per share for the quarter, topping analysts' consensus estimates of $1.28 by $0.73. The company had revenue of 649.73 M for the quarter and had revenue of 2.67 B for the year. Bio-Rad Laboratories, Inc. has generated $-22 earnings per share over the last year ($-21.82 diluted earnings per share) and currently has a price-to-earnings ratio of -13.54. Bio-Rad Laboratories, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 13th, 2025 based on prior year's report dates.
Bio-Rad Laboratories, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 10/31/2024 | Q3 2024 | $23.09 | $628.18 M | $649.73 M | ||
| 08/02/2024 | Q2 2024 | -$76.26 | $645.79 M | $638.48 M | ||
| 05/08/2024 | Q1 2024 | $13.46 | $610.82 M | |||
| 02/16/2024 | Q4 2023 | $12.15 | $681.18 M | |||
| 10/27/2023 | Q3 2023 | $3.65 | $689.50 M | $632.12 M | ||
| 08/04/2023 | Q2 2023 | -$39.59 | $697.96 M | $681.11 M | ||
| 05/05/2023 | Q1 2023 | $2.33 | $676.84 M | |||
| 02/17/2023 | Q4 2022 | $27.89 | $730.29 M | |||
| 10/28/2022 | Q3 2022 | -$5.53 | $679.94 M | $680.80 M | ||
| 07/29/2022 | Q2 2022 | -$31.12 | $682.62 M | $691.10 M | ||
| 04/29/2022 | Q1 2022 | -$112.58 | $700.06 M | |||
| 02/11/2022 | Q4 2021 | -$52.59 | $732.77 M | |||
| 10/29/2021 | Q3 2021 | $131.75 | $664.57 M | $747.05 M | ||
| 07/30/2021 | Q2 2021 | $30.71 | $646.07 M | $715.93 M | ||
| 04/30/2021 | Q1 2021 | $32.77 | $726.80 M | |||
| 02/12/2021 | Q4 2020 | $28.13 | $789.84 M | |||
| 10/30/2020 | Q3 2020 | $44.24 | $570.57 M | $647.26 M | ||
| 07/31/2020 | Q2 2020 | $32.59 | $517.06 M | $536.88 M | ||
| 05/07/2020 | Q1 2020 | $22.97 | $571.64 M | |||
| 03/02/2020 | Q4 2019 | $18.50 | $624.43 M |
Bio-Rad Laboratories, Inc. Earnings: Frequently Asked Questions
-
When is Bio-Rad Laboratories, Inc.'s earnings date?
Bio-Rad Laboratories, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 13th, 2025 based off last year's report dates.
-
Did Bio-Rad Laboratories, Inc. beat their earnings estimates last quarter?
In the previous quarter, Bio-Rad Laboratories, Inc. (:BIO) reported $2.01 earnings per share (EPS) to beat the analysts' consensus estimate of $1.28 by $0.73.
-
How can I listen to Bio-Rad Laboratories, Inc.'s earnings conference call?
The conference call for Bio-Rad Laboratories, Inc.'s latest earnings report can be listened to online.
-
How can I read Bio-Rad Laboratories, Inc.'s conference call transcript?
The conference call transcript for Bio-Rad Laboratories, Inc.'s latest earnings report can be read online.
-
How much revenue does Bio-Rad Laboratories, Inc. generate each year?
Bio-Rad Laboratories, Inc. (:BIO) has a recorded annual revenue of $2.67 B.
-
How much profit does Bio-Rad Laboratories, Inc. generate each year?
Bio-Rad Laboratories, Inc. (:BIO) has a recorded net income of $2.67 B. Bio-Rad Laboratories, Inc. has generated $-21.82 earnings per share over the last four quarters.
-
What is Bio-Rad Laboratories, Inc.'s price-to-earnings ratio?
Bio-Rad Laboratories, Inc. (:BIO) has a price-to-earnings ratio of -13.54 and price/earnings-to-growth ratio is -0.33.
